TIL - At a Recent Cancer Research Conference Instil Bio Stole the Show
At the mid-April American Association of Cancer Research Annual Meeting, bleeding-edge oncology company Instil Bio (NASDAQ: TIL) reported promising results for one of its candidate therapies.
In a compassionate-use program, the company's tumor-infiltrating lymphocyte (TIL) therapy had an impressive overall response rate in an especially difficult-to-treat stage IV metastatic melanoma population. The $2.1 billion market cap biotech expects to begin a phase 2 trial of the treatment in the second half of 2021, with data to be delivered in 2023. Here's what biotech investors need to know from this encouraging development and Instil's potential.
For further details see:
At a Recent Cancer Research Conference, Instil Bio Stole the Show